Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection

Nancy Reau, Paul Y. Kwo, Susan Rhee, Robert S. Brown, Kosh Agarwal, Peter Angus, Edward Gane, Jia‐Horng Kao, Parvez S. Mantry, David Mutimer, K. Rajender Reddy, Tram T. Tran, Yiran B. Hu, Abhishek Gulati, Preethi Krishnan, Emily O. Dumas, Ariel Porcalla, Nancy S. Shulman, Wei Liu, Suvajit Samanta, Roger Trinh, Xavier Forns – 19 April 2018 – Well‐tolerated, ribavirin‐free, pangenotypic hepatitis C virus (HCV) treatments for transplant recipients remain a high priority.

Cirrhotic Cardiomyopathy After Transplantation: Neither the Transient Nor Innocent Bystander

Manhal Izzy, Jae Oh, Kymberly D. Watt – 19 April 2018 – Cirrhotic cardiomyopathy in end‐stage liver disease is currently characterized by blunted contractile systolic response to stress with or without diastolic dysfunction in the absence of known heart disease. Since the establishment of the diagnostic criteria of cirrhotic cardiomyopathy in 2005, there have been multiple studies regarding its pathophysiology and pretransplant clinical course. The data regarding the post‐transplant course of this entity are sparse.

Fibroblast Growth Factor 15–Dependent and Bile Acid–Independent Promotion of Liver Regeneration in Mice

Bo Kong, Runbin Sun, Mingxing Huang, Monica D. Chow, Xiao‐Bo Zhong, Wen Xie, Yi‐Horng Lee, Grace L. Guo – 19 April 2018 – The role of intestine‐derived factors in promoting liver regeneration after partial hepatectomy (PHx) are not entirely known, but bile acids (BAs) and fibroblast growth factor 15 (Fgf15) that is highly expressed in the mouse ileum could promote hepatocyte proliferation. Fgf15 strongly suppresses the synthesis of BAs, and emerging evidence indicates that Fgf15 is important for liver regeneration.

Subscribe to